Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + Clarithromycin for First-line H. Pylori Eradication
NCT07439445Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan and clarithromycin in Helicobacter pylori infection, sponsored by Peking University First Hospital. Primary endpoint: Eradication rate of H. pylori. Started Apr 2026; status: recruiting.
02
Drugs
vonoprazanclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07439445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439445.